Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

APLS – Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.
APLS
$17.43
Name : Apellis Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,190,637,312.00
EPSttm : -1.8
finviz dynamic chart for APLS
Apellis Pharmaceuticals, Inc.
$17.43
5.27%
$0.97

Float Short %

24.32

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

0.36

EPS Last/This Y

-0.26

EPS This/Next Y

1.13

Price

17.42

Target Price

35.35

Analyst Recom

1.87

Performance Q

-28.21

Relative Volume

1.26

Beta

0.68

Ticker: APLS




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02APLS19.130.250.6849656
2025-06-03APLS18.820.250.4050080
2025-06-04APLS18.510.250.6350240
2025-06-05APLS19.080.250.4850300
2025-06-06APLS19.280.251.2750504
2025-06-09APLS19.360.260.3450735
2025-06-10APLS19.590.260.1050753
2025-06-11APLS19.270.260.2550775
2025-06-12APLS19.280.260.1250866
2025-06-13APLS18.820.260.0950926
2025-06-16APLS18.30.260.6950897
2025-06-17APLS17.750.260.1850961
2025-06-18APLS17.780.260.1450647
2025-06-20APLS17.680.260.7550701
2025-06-23APLS17.70.250.3947509
2025-06-24APLS18.610.250.0247612
2025-06-25APLS18.390.240.0849249
2025-06-26APLS18.40.240.0350874
2025-06-27APLS17.430.240.0050601
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02APLS19.13-52.153.5-1.91
2025-06-03APLS18.82-55.069.0-1.91
2025-06-04APLS18.50-55.069.0-1.91
2025-06-05APLS19.10-55.063.8-1.89
2025-06-06APLS19.28-60.666.2-1.86
2025-06-09APLS19.39-60.626.5-1.86
2025-06-10APLS19.59-60.625.9-1.87
2025-06-11APLS19.29-60.629.5-1.87
2025-06-12APLS19.26-60.627.4-1.87
2025-06-13APLS18.84-60.630.5-1.87
2025-06-16APLS18.28-60.631.5-1.87
2025-06-17APLS17.75-60.631.6-1.87
2025-06-18APLS17.76-60.627.2-1.87
2025-06-20APLS17.69-60.627.9-1.87
2025-06-23APLS17.64-60.627.6-1.87
2025-06-24APLS18.60-60.619.3-1.87
2025-06-25APLS18.39-60.629.1-1.87
2025-06-26APLS18.38-60.227.4-1.86
2025-06-27APLS17.42-60.235.0-1.86
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02APLS-0.472.5226.30
2025-06-03APLS-0.472.5226.30
2025-06-04APLS-0.472.5226.30
2025-06-05APLS-0.472.5226.30
2025-06-06APLS-0.472.5226.30
2025-06-09APLS-0.472.5326.30
2025-06-10APLS-0.472.5326.30
2025-06-11APLS-0.472.5324.17
2025-06-12APLS-0.462.5324.22
2025-06-13APLS-0.462.5324.22
2025-06-16APLS-0.442.5124.22
2025-06-17APLS-0.442.5124.22
2025-06-18APLS-0.462.5124.22
2025-06-20APLS-0.462.5124.22
2025-06-23APLS-0.462.5224.22
2025-06-24APLS-0.462.5224.22
2025-06-25APLS-0.462.5224.22
2025-06-26APLS-0.462.5224.32
2025-06-27APLS-0.462.5224.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.74

Avg. EPS Est. Current Quarter

-0.46

Avg. EPS Est. Next Quarter

-0.38

Insider Transactions

-0.46

Institutional Transactions

2.52

Beta

0.68

Average Sales Estimate Current Quarter

186

Average Sales Estimate Next Quarter

201

Fair Value

Quality Score

40

Growth Score

41

Sentiment Score

39

Actual DrawDown %

81.6

Max Drawdown 5-Year %

-82.5

Target Price

35.35

P/E

Forward P/E

PEG

P/S

2.82

P/B

13.34

P/Free Cash Flow

EPS

-1.79

Average EPS Est. Cur. Y​

-1.86

EPS Next Y. (Est.)

-0.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-28.83

Relative Volume

1.26

Return on Equity vs Sector %

-160.1

Return on Equity vs Industry %

-142.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.12

EBIT Estimation

35
Apellis Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 705
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
stock quote shares APLS – Apellis Pharmaceuticals, Inc. Stock Price stock today
news today APLS – Apellis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch APLS – Apellis Pharmaceuticals, Inc. yahoo finance google finance
stock history APLS – Apellis Pharmaceuticals, Inc. invest stock market
stock prices APLS premarket after hours
ticker APLS fair value insiders trading